Clinical Trials
15 trialsNCT04904185 2025-07-25
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Herlev Hospital
Phase 1 Terminated
NCT01218867 2019-12-10
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00670748 2019-11-19
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02111863 2017-09-19
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01271907 2017-08-01
Drosophila-generated CTL
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00610311 2015-10-28
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00612222 2015-10-28
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00704938 2015-10-28
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01369888 2015-01-27
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00303836 2013-06-06
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00509496 2013-01-15
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00924001 2012-10-25
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00138229 2012-03-29
Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated